Abstract
Following chemotherapy for metastatic nonseminomatous testicular cancer, 86 patients with normal serum markers AFP and HCG underwent resection of residual tumour masses (63 laparotomy, 11 thoracotomy, 12 both). Prognostic factors for relapse and survival were analysed with Kaplan-Meier curves and Cox regression analysis. Putative prognostic factors included age, the primary histology, prechemotherapy level of the tumour markers AFP and HCG, the extent of disease (lymph nodes, lung and hepatic metastases) before and after chemotherapy, the histology of the resected material and the completeness of the surgical procedure. Eleven patients relapsed during follow-up (median 47 months), accounting for a 5 year relapse free percentage of 87.4%. Adverse prognostic factors were (1) prechemotherapy level of HCG (> or = 10,000 IU l-1; (2) incomplete resection; and (3) the extent of disease, especially of lung metastases (prechemotherapy number < or = 3,4-19, > or = 20; or size after chemotherapy > 1 cm; or presence of any residual lung metastasis after chemotherapy without residual abdominal metastases). The histology found at resection was not associated with the risk of relapse, which might be explained by the effectiveness of postresection chemotherapy, which in the majority of these patients was a salvage regimen rather than two further cycles of the initial cytostatics. A good and a poor risk group were formed, based on HCG level and completeness of resection. The effect of salvage chemotherapy after resection of viable cancer cells needs further investigation.
MeSH Terms
Adult
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Dysgerminoma/drug therapy,mortality,surgery
Follow-Up Studies
Humans
Male
Multivariate Analysis
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Retrospective Studies
Survival Analysis
Teratoma/drug therapy,mortality,pathology,surgery
Testicular Neoplasms/drug therapy,mortality,pathology,surgery
Time Factors
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Steyerberg E W
Department of Clinical Oncology, Urology and Thoracic Surgery, University Hospital Leiden, The Netherlands.
Keizer H J
Zwartendijk J
Van Rijk G L
Van Groeningen C J
Habbema J D
Stoter G
References (18)
18 references, click to expand
-
Non-seminomatous germ cell testicular tumours: residual masses after chemotherapy.
Br J Surg. 1985 Jan;72(1):19-22
PMID: 2578300
-
Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
J Clin Oncol. 1992 Apr;10(4):569-73
PMID: 1312586
-
Testicular cancer.
Acta Oncol. 1988;27(4):439-53
PMID: 3060153
-
Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors.
Cancer. 1989 Feb 1;63(3):440-5
PMID: 2912523
-
The role of surgery in metastatic testicular germ cell tumours (GCT).
Br J Cancer. 1989 Jun;59(6):837-9
PMID: 2544224
-
Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin.
J Clin Oncol. 1989 Aug;7(8):1099-104
PMID: 2474060
-
Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours.
Eur J Cancer Clin Oncol. 1989 Dec;25(12):1689-94
PMID: 2561098
-
The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours.
Br J Urol. 1990 Oct;66(4):425-9
PMID: 2224438
-
Evaluation of survival data and two new rank order statistics arising in its consideration.
Cancer Chemother Rep. 1966 Mar;50(3):163-70
PMID: 5910392
-
Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma.
Br J Cancer. 1984 Nov;50(5):601-9
PMID: 6093838
-
The role of surgery in advanced testicular cancer.
Cancer. 1984 Dec 1;54(11 Suppl):2716-21
PMID: 6388814
-
Treatment of testicular cancer: a new and improved model.
J Clin Oncol. 1990 Nov;8(11):1777-81
PMID: 1700077
-
Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
J Clin Oncol. 1991 May;9(5):818-26
PMID: 1707957
-
Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.
Eur J Cancer. 1991;27(6):684-91
PMID: 1712606
-
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)
Eur J Cancer. 1991;27(6):695-8
PMID: 1829907
-
Assessment of risk in metastatic testis carcinoma: impact on treatment.
Urol Int. 1991;46(3):298-303
PMID: 1656578
-
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
J Clin Oncol. 1992 Jan;10(1):85-94
PMID: 1309383
-
Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer.
J Urol. 1987 Jun;137(6):1176-9
PMID: 3035236